Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H18FN7O |
Molecular Weight | 415.423 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@H](NC1=C2N=CNC2=NC=N1)C3=NC4=C(C(=O)N3C5=CC=CC=C5)C(F)=CC=C4
InChI
InChIKey=IFSDAJWBUCMOAH-HNNXBMFYSA-N
InChI=1S/C22H18FN7O/c1-2-15(28-20-18-19(25-11-24-18)26-12-27-20)21-29-16-10-6-9-14(23)17(16)22(31)30(21)13-7-4-3-5-8-13/h3-12,15H,2H2,1H3,(H2,24,25,26,27,28)/t15-/m0/s1
Molecular Formula | C22H18FN7O |
Molecular Weight | 415.423 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including
http://link.springer.com/article/10.1007/s40265-014-0285-6
Curator's Comment: description was created based on several sources, including
http://link.springer.com/article/10.1007/s40265-014-0285-6
Idelalisib is a first-in-class selective inhibitor of adenosine-5'-triphosphate (ATP) binding to PI3Kdelta kinase, resulting in inhibition of the P13K signalling pathway in malignant B cells. The compound is approved for the treatment of several types of blood cancer. Idelalisib is intended to be used in combination with rituximab as second or subsequent line therapy for the treatment of chronic lymphocytic leukaemia. The drug may cause fatal and/or severe diarrhea or colitis, hepatotoxicity, pneumonitis and intestinal perforation.
CNS Activity
Sources: http://www.ncbi.nlm.nih.gov/pubmed/26239089
Curator's Comment: Ibrutinib can cross the blood-brain barrier (1–7% of the dose found in cerebral spinal fluid).
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3130 Sources: http://www.ncbi.nlm.nih.gov/pubmed/?term=20959606 |
2.5 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ZYDELIG Approved UseIndicated for the treatment of patients with: 1) relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities; 2) relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patients who have received at least two prior systemic therapies; 3) relapsed small lymphocytic lymphoma (SLL) in patients who have received at least two prior systemic therapies. Launch Date2014 |
|||
Primary | ZYDELIG Approved UseIndicated for the treatment of patients with: 1) relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities; 2) relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patients who have received at least two prior systemic therapies; 3) relapsed small lymphocytic lymphoma (SLL) in patients who have received at least two prior systemic therapies. Launch Date2014 |
|||
Primary | ZYDELIG Approved UseIndicated for the treatment of patients with: 1) relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities; 2) relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patients who have received at least two prior systemic therapies; 3) relapsed small lymphocytic lymphoma (SLL) in patients who have received at least two prior systemic therapies. Launch Date2014 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.953 ng/mL |
150 mg 2 times / day steady-state, oral dose: 150 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
IDELALISIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2647.5 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01282424 |
150 mg single, oral dose: 150 mg route of administration: oral experiment type: single co-administered: |
IDELALISIB plasma | Homo sapiens population: unhealthy age: sex: food status: |
|
2258.8 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01282424 |
150 mg 2 times / day multiple, oral dose: 150 mg route of administration: oral experiment type: multiple co-administered: |
IDELALISIB plasma | Homo sapiens population: unhealthy age: sex: food status: |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10.439 ng × h/mL |
150 mg 2 times / day steady-state, oral dose: 150 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
IDELALISIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
9094.76 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01282424 |
150 mg single, oral dose: 150 mg route of administration: oral experiment type: single co-administered: |
IDELALISIB plasma | Homo sapiens population: unhealthy age: sex: food status: |
|
9293.39 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01282424 |
150 mg 2 times / day multiple, oral dose: 150 mg route of administration: oral experiment type: multiple co-administered: |
IDELALISIB plasma | Homo sapiens population: unhealthy age: sex: food status: |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8.2 h |
150 mg 2 times / day steady-state, oral dose: 150 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
IDELALISIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
350 mg 2 times / day multiple, oral Highest studied dose Dose: 350 mg, 2 times / day Route: oral Route: multiple Dose: 350 mg, 2 times / day Sources: |
unhealthy, 64 years (range: 32-91 years) n = 4 Health Status: unhealthy Condition: non-Hodgkin lymphoma Age Group: 64 years (range: 32-91 years) Sex: M+F Population Size: 4 Sources: |
Other AEs: Diarrhea, Pneumonia... Other AEs: Diarrhea (grade 3, 25%) Sources: Pneumonia (grade 3, 25%) Edema peripheral (grade 3, 25%) AST increased (grade 3, 50%) ALT increased (grade 3, 50%) Absolute neutrophil count decreased (grade 3, 50%) Platelets decreased (grade 3, 50%) Vomiting (all grades, 25%) Rash (all grades, 25%) Chills (all grades, 25%) Fatigue (all grades, 25%) Constipation (all grades, 25%) Nausea (all grades, 25%) Insomnia (all grades, 25%) Edema peripheral (all grades, 25%) Arterial pressure NOS increased (all grades, 25%) Bilirubin increased (all grades, 25%) Glucose increased (all grades, 25%) Glucose decreased (all grades, 25%) Hemoglobin decreased (all grades, 25%) Pyrexia (all grades, 25%) Night sweats (all grades, 25%) |
150 mg 2 times / day steady, oral Recommended Dose: 150 mg, 2 times / day Route: oral Route: steady Dose: 150 mg, 2 times / day Sources: |
unhealthy, 71 years (range: 47 - 92 years) n = 110 Health Status: unhealthy Condition: Relapsed Chronic Lymphocytic Leukemia Age Group: 71 years (range: 47 - 92 years) Sex: M+F Population Size: 110 Sources: |
Disc. AE: Hepatotoxicity, Diarrhea... AEs leading to discontinuation/dose reduction: Hepatotoxicity (10%) Sources: Diarrhea (10%) Colitis (10%) Transaminases increased (15%) Diarrhea (15%) Colitis (15%) Rash (15%) |
150 mg 2 times / day steady, oral Recommended Dose: 150 mg, 2 times / day Route: oral Route: steady Dose: 150 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Other AEs: Hepatotoxicity, Diarrhea... Other AEs: Hepatotoxicity (serious|grade 5, 14%) Sources: Diarrhea (serious|grade 5, 14%) Colitis (serious|grade 5, 14%) Pneumonitis (serious|grade 5) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Arterial pressure NOS increased | all grades, 25% | 350 mg 2 times / day multiple, oral Highest studied dose Dose: 350 mg, 2 times / day Route: oral Route: multiple Dose: 350 mg, 2 times / day Sources: |
unhealthy, 64 years (range: 32-91 years) n = 4 Health Status: unhealthy Condition: non-Hodgkin lymphoma Age Group: 64 years (range: 32-91 years) Sex: M+F Population Size: 4 Sources: |
Bilirubin increased | all grades, 25% | 350 mg 2 times / day multiple, oral Highest studied dose Dose: 350 mg, 2 times / day Route: oral Route: multiple Dose: 350 mg, 2 times / day Sources: |
unhealthy, 64 years (range: 32-91 years) n = 4 Health Status: unhealthy Condition: non-Hodgkin lymphoma Age Group: 64 years (range: 32-91 years) Sex: M+F Population Size: 4 Sources: |
Chills | all grades, 25% | 350 mg 2 times / day multiple, oral Highest studied dose Dose: 350 mg, 2 times / day Route: oral Route: multiple Dose: 350 mg, 2 times / day Sources: |
unhealthy, 64 years (range: 32-91 years) n = 4 Health Status: unhealthy Condition: non-Hodgkin lymphoma Age Group: 64 years (range: 32-91 years) Sex: M+F Population Size: 4 Sources: |
Constipation | all grades, 25% | 350 mg 2 times / day multiple, oral Highest studied dose Dose: 350 mg, 2 times / day Route: oral Route: multiple Dose: 350 mg, 2 times / day Sources: |
unhealthy, 64 years (range: 32-91 years) n = 4 Health Status: unhealthy Condition: non-Hodgkin lymphoma Age Group: 64 years (range: 32-91 years) Sex: M+F Population Size: 4 Sources: |
Edema peripheral | all grades, 25% | 350 mg 2 times / day multiple, oral Highest studied dose Dose: 350 mg, 2 times / day Route: oral Route: multiple Dose: 350 mg, 2 times / day Sources: |
unhealthy, 64 years (range: 32-91 years) n = 4 Health Status: unhealthy Condition: non-Hodgkin lymphoma Age Group: 64 years (range: 32-91 years) Sex: M+F Population Size: 4 Sources: |
Fatigue | all grades, 25% | 350 mg 2 times / day multiple, oral Highest studied dose Dose: 350 mg, 2 times / day Route: oral Route: multiple Dose: 350 mg, 2 times / day Sources: |
unhealthy, 64 years (range: 32-91 years) n = 4 Health Status: unhealthy Condition: non-Hodgkin lymphoma Age Group: 64 years (range: 32-91 years) Sex: M+F Population Size: 4 Sources: |
Glucose decreased | all grades, 25% | 350 mg 2 times / day multiple, oral Highest studied dose Dose: 350 mg, 2 times / day Route: oral Route: multiple Dose: 350 mg, 2 times / day Sources: |
unhealthy, 64 years (range: 32-91 years) n = 4 Health Status: unhealthy Condition: non-Hodgkin lymphoma Age Group: 64 years (range: 32-91 years) Sex: M+F Population Size: 4 Sources: |
Glucose increased | all grades, 25% | 350 mg 2 times / day multiple, oral Highest studied dose Dose: 350 mg, 2 times / day Route: oral Route: multiple Dose: 350 mg, 2 times / day Sources: |
unhealthy, 64 years (range: 32-91 years) n = 4 Health Status: unhealthy Condition: non-Hodgkin lymphoma Age Group: 64 years (range: 32-91 years) Sex: M+F Population Size: 4 Sources: |
Hemoglobin decreased | all grades, 25% | 350 mg 2 times / day multiple, oral Highest studied dose Dose: 350 mg, 2 times / day Route: oral Route: multiple Dose: 350 mg, 2 times / day Sources: |
unhealthy, 64 years (range: 32-91 years) n = 4 Health Status: unhealthy Condition: non-Hodgkin lymphoma Age Group: 64 years (range: 32-91 years) Sex: M+F Population Size: 4 Sources: |
Insomnia | all grades, 25% | 350 mg 2 times / day multiple, oral Highest studied dose Dose: 350 mg, 2 times / day Route: oral Route: multiple Dose: 350 mg, 2 times / day Sources: |
unhealthy, 64 years (range: 32-91 years) n = 4 Health Status: unhealthy Condition: non-Hodgkin lymphoma Age Group: 64 years (range: 32-91 years) Sex: M+F Population Size: 4 Sources: |
Nausea | all grades, 25% | 350 mg 2 times / day multiple, oral Highest studied dose Dose: 350 mg, 2 times / day Route: oral Route: multiple Dose: 350 mg, 2 times / day Sources: |
unhealthy, 64 years (range: 32-91 years) n = 4 Health Status: unhealthy Condition: non-Hodgkin lymphoma Age Group: 64 years (range: 32-91 years) Sex: M+F Population Size: 4 Sources: |
Night sweats | all grades, 25% | 350 mg 2 times / day multiple, oral Highest studied dose Dose: 350 mg, 2 times / day Route: oral Route: multiple Dose: 350 mg, 2 times / day Sources: |
unhealthy, 64 years (range: 32-91 years) n = 4 Health Status: unhealthy Condition: non-Hodgkin lymphoma Age Group: 64 years (range: 32-91 years) Sex: M+F Population Size: 4 Sources: |
Pyrexia | all grades, 25% | 350 mg 2 times / day multiple, oral Highest studied dose Dose: 350 mg, 2 times / day Route: oral Route: multiple Dose: 350 mg, 2 times / day Sources: |
unhealthy, 64 years (range: 32-91 years) n = 4 Health Status: unhealthy Condition: non-Hodgkin lymphoma Age Group: 64 years (range: 32-91 years) Sex: M+F Population Size: 4 Sources: |
Rash | all grades, 25% | 350 mg 2 times / day multiple, oral Highest studied dose Dose: 350 mg, 2 times / day Route: oral Route: multiple Dose: 350 mg, 2 times / day Sources: |
unhealthy, 64 years (range: 32-91 years) n = 4 Health Status: unhealthy Condition: non-Hodgkin lymphoma Age Group: 64 years (range: 32-91 years) Sex: M+F Population Size: 4 Sources: |
Vomiting | all grades, 25% | 350 mg 2 times / day multiple, oral Highest studied dose Dose: 350 mg, 2 times / day Route: oral Route: multiple Dose: 350 mg, 2 times / day Sources: |
unhealthy, 64 years (range: 32-91 years) n = 4 Health Status: unhealthy Condition: non-Hodgkin lymphoma Age Group: 64 years (range: 32-91 years) Sex: M+F Population Size: 4 Sources: |
Diarrhea | grade 3, 25% | 350 mg 2 times / day multiple, oral Highest studied dose Dose: 350 mg, 2 times / day Route: oral Route: multiple Dose: 350 mg, 2 times / day Sources: |
unhealthy, 64 years (range: 32-91 years) n = 4 Health Status: unhealthy Condition: non-Hodgkin lymphoma Age Group: 64 years (range: 32-91 years) Sex: M+F Population Size: 4 Sources: |
Edema peripheral | grade 3, 25% | 350 mg 2 times / day multiple, oral Highest studied dose Dose: 350 mg, 2 times / day Route: oral Route: multiple Dose: 350 mg, 2 times / day Sources: |
unhealthy, 64 years (range: 32-91 years) n = 4 Health Status: unhealthy Condition: non-Hodgkin lymphoma Age Group: 64 years (range: 32-91 years) Sex: M+F Population Size: 4 Sources: |
Pneumonia | grade 3, 25% | 350 mg 2 times / day multiple, oral Highest studied dose Dose: 350 mg, 2 times / day Route: oral Route: multiple Dose: 350 mg, 2 times / day Sources: |
unhealthy, 64 years (range: 32-91 years) n = 4 Health Status: unhealthy Condition: non-Hodgkin lymphoma Age Group: 64 years (range: 32-91 years) Sex: M+F Population Size: 4 Sources: |
ALT increased | grade 3, 50% | 350 mg 2 times / day multiple, oral Highest studied dose Dose: 350 mg, 2 times / day Route: oral Route: multiple Dose: 350 mg, 2 times / day Sources: |
unhealthy, 64 years (range: 32-91 years) n = 4 Health Status: unhealthy Condition: non-Hodgkin lymphoma Age Group: 64 years (range: 32-91 years) Sex: M+F Population Size: 4 Sources: |
AST increased | grade 3, 50% | 350 mg 2 times / day multiple, oral Highest studied dose Dose: 350 mg, 2 times / day Route: oral Route: multiple Dose: 350 mg, 2 times / day Sources: |
unhealthy, 64 years (range: 32-91 years) n = 4 Health Status: unhealthy Condition: non-Hodgkin lymphoma Age Group: 64 years (range: 32-91 years) Sex: M+F Population Size: 4 Sources: |
Absolute neutrophil count decreased | grade 3, 50% | 350 mg 2 times / day multiple, oral Highest studied dose Dose: 350 mg, 2 times / day Route: oral Route: multiple Dose: 350 mg, 2 times / day Sources: |
unhealthy, 64 years (range: 32-91 years) n = 4 Health Status: unhealthy Condition: non-Hodgkin lymphoma Age Group: 64 years (range: 32-91 years) Sex: M+F Population Size: 4 Sources: |
Platelets decreased | grade 3, 50% | 350 mg 2 times / day multiple, oral Highest studied dose Dose: 350 mg, 2 times / day Route: oral Route: multiple Dose: 350 mg, 2 times / day Sources: |
unhealthy, 64 years (range: 32-91 years) n = 4 Health Status: unhealthy Condition: non-Hodgkin lymphoma Age Group: 64 years (range: 32-91 years) Sex: M+F Population Size: 4 Sources: |
Colitis | 10% Disc. AE |
150 mg 2 times / day steady, oral Recommended Dose: 150 mg, 2 times / day Route: oral Route: steady Dose: 150 mg, 2 times / day Sources: |
unhealthy, 71 years (range: 47 - 92 years) n = 110 Health Status: unhealthy Condition: Relapsed Chronic Lymphocytic Leukemia Age Group: 71 years (range: 47 - 92 years) Sex: M+F Population Size: 110 Sources: |
Diarrhea | 10% Disc. AE |
150 mg 2 times / day steady, oral Recommended Dose: 150 mg, 2 times / day Route: oral Route: steady Dose: 150 mg, 2 times / day Sources: |
unhealthy, 71 years (range: 47 - 92 years) n = 110 Health Status: unhealthy Condition: Relapsed Chronic Lymphocytic Leukemia Age Group: 71 years (range: 47 - 92 years) Sex: M+F Population Size: 110 Sources: |
Hepatotoxicity | 10% Disc. AE |
150 mg 2 times / day steady, oral Recommended Dose: 150 mg, 2 times / day Route: oral Route: steady Dose: 150 mg, 2 times / day Sources: |
unhealthy, 71 years (range: 47 - 92 years) n = 110 Health Status: unhealthy Condition: Relapsed Chronic Lymphocytic Leukemia Age Group: 71 years (range: 47 - 92 years) Sex: M+F Population Size: 110 Sources: |
Colitis | 15% Disc. AE |
150 mg 2 times / day steady, oral Recommended Dose: 150 mg, 2 times / day Route: oral Route: steady Dose: 150 mg, 2 times / day Sources: |
unhealthy, 71 years (range: 47 - 92 years) n = 110 Health Status: unhealthy Condition: Relapsed Chronic Lymphocytic Leukemia Age Group: 71 years (range: 47 - 92 years) Sex: M+F Population Size: 110 Sources: |
Diarrhea | 15% Disc. AE |
150 mg 2 times / day steady, oral Recommended Dose: 150 mg, 2 times / day Route: oral Route: steady Dose: 150 mg, 2 times / day Sources: |
unhealthy, 71 years (range: 47 - 92 years) n = 110 Health Status: unhealthy Condition: Relapsed Chronic Lymphocytic Leukemia Age Group: 71 years (range: 47 - 92 years) Sex: M+F Population Size: 110 Sources: |
Rash | 15% Disc. AE |
150 mg 2 times / day steady, oral Recommended Dose: 150 mg, 2 times / day Route: oral Route: steady Dose: 150 mg, 2 times / day Sources: |
unhealthy, 71 years (range: 47 - 92 years) n = 110 Health Status: unhealthy Condition: Relapsed Chronic Lymphocytic Leukemia Age Group: 71 years (range: 47 - 92 years) Sex: M+F Population Size: 110 Sources: |
Transaminases increased | 15% Disc. AE |
150 mg 2 times / day steady, oral Recommended Dose: 150 mg, 2 times / day Route: oral Route: steady Dose: 150 mg, 2 times / day Sources: |
unhealthy, 71 years (range: 47 - 92 years) n = 110 Health Status: unhealthy Condition: Relapsed Chronic Lymphocytic Leukemia Age Group: 71 years (range: 47 - 92 years) Sex: M+F Population Size: 110 Sources: |
Pneumonitis | serious|grade 5 | 150 mg 2 times / day steady, oral Recommended Dose: 150 mg, 2 times / day Route: oral Route: steady Dose: 150 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Colitis | serious|grade 5, 14% | 150 mg 2 times / day steady, oral Recommended Dose: 150 mg, 2 times / day Route: oral Route: steady Dose: 150 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Diarrhea | serious|grade 5, 14% | 150 mg 2 times / day steady, oral Recommended Dose: 150 mg, 2 times / day Route: oral Route: steady Dose: 150 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Hepatotoxicity | serious|grade 5, 14% | 150 mg 2 times / day steady, oral Recommended Dose: 150 mg, 2 times / day Route: oral Route: steady Dose: 150 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Drug as victim
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205858Orig1s000ClinPharmR.pdf#page=19 Page: 19.0 |
PubMed
Title | Date | PubMed |
---|---|---|
CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. | 2011 Jan 13 |
|
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. | 2014 Mar 13 |
|
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. | 2014 May 29 |
|
Clinical drug interaction profile of idelalisib in healthy subjects. | 2015 Aug |
Patents
Sample Use Guides
The recommended dose is 150 mg taken orally, twice daily
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/?term=24659719
Treatment of primary CLL cells (n =14) co-cultured with HS5 stromal cells with 100 nM idelalisib results in decreased AKT phosphorylation and inhibition of BCR mediated signaling pathways.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 01:29:15 GMT 2023
by
admin
on
Sat Dec 16 01:29:15 GMT 2023
|
Record UNII |
YG57I8T5M0
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
405913
Created by
admin on Sat Dec 16 01:29:15 GMT 2023 , Edited by admin on Sat Dec 16 01:29:15 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
ZYDELIG (AUTHORIZED: LYMPHOMA, NON-HODGKIN)
Created by
admin on Sat Dec 16 01:29:15 GMT 2023 , Edited by admin on Sat Dec 16 01:29:15 GMT 2023
|
||
|
NCI_THESAURUS |
C129825
Created by
admin on Sat Dec 16 01:29:15 GMT 2023 , Edited by admin on Sat Dec 16 01:29:15 GMT 2023
|
||
|
FDA ORPHAN DRUG |
405813
Created by
admin on Sat Dec 16 01:29:15 GMT 2023 , Edited by admin on Sat Dec 16 01:29:15 GMT 2023
|
||
|
WHO-ATC |
L01XX47
Created by
admin on Sat Dec 16 01:29:15 GMT 2023 , Edited by admin on Sat Dec 16 01:29:15 GMT 2023
|
||
|
NDF-RT |
N0000175605
Created by
admin on Sat Dec 16 01:29:15 GMT 2023 , Edited by admin on Sat Dec 16 01:29:15 GMT 2023
|
||
|
FDA ORPHAN DRUG |
405613
Created by
admin on Sat Dec 16 01:29:15 GMT 2023 , Edited by admin on Sat Dec 16 01:29:15 GMT 2023
|
||
|
FDA ORPHAN DRUG |
412613
Created by
admin on Sat Dec 16 01:29:15 GMT 2023 , Edited by admin on Sat Dec 16 01:29:15 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
ZYDELIG (AUTHORIZED: LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL)
Created by
admin on Sat Dec 16 01:29:15 GMT 2023 , Edited by admin on Sat Dec 16 01:29:15 GMT 2023
|
||
|
FDA ORPHAN DRUG |
405713
Created by
admin on Sat Dec 16 01:29:15 GMT 2023 , Edited by admin on Sat Dec 16 01:29:15 GMT 2023
|
||
|
EU-Orphan Drug |
EU/3/13/1160
Created by
admin on Sat Dec 16 01:29:15 GMT 2023 , Edited by admin on Sat Dec 16 01:29:15 GMT 2023
|
||
|
FDA ORPHAN DRUG |
347511
Created by
admin on Sat Dec 16 01:29:15 GMT 2023 , Edited by admin on Sat Dec 16 01:29:15 GMT 2023
|
||
|
NCI_THESAURUS |
C2152
Created by
admin on Sat Dec 16 01:29:15 GMT 2023 , Edited by admin on Sat Dec 16 01:29:15 GMT 2023
|
||
|
FDA ORPHAN DRUG |
412513
Created by
admin on Sat Dec 16 01:29:15 GMT 2023 , Edited by admin on Sat Dec 16 01:29:15 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB09054
Created by
admin on Sat Dec 16 01:29:15 GMT 2023 , Edited by admin on Sat Dec 16 01:29:15 GMT 2023
|
PRIMARY | |||
|
N0000175082
Created by
admin on Sat Dec 16 01:29:15 GMT 2023 , Edited by admin on Sat Dec 16 01:29:15 GMT 2023
|
PRIMARY | Kinase Inhibitors [MoA] | ||
|
100000151771
Created by
admin on Sat Dec 16 01:29:15 GMT 2023 , Edited by admin on Sat Dec 16 01:29:15 GMT 2023
|
PRIMARY | |||
|
1544460
Created by
admin on Sat Dec 16 01:29:15 GMT 2023 , Edited by admin on Sat Dec 16 01:29:15 GMT 2023
|
PRIMARY | RxNorm | ||
|
Idelalisib
Created by
admin on Sat Dec 16 01:29:15 GMT 2023 , Edited by admin on Sat Dec 16 01:29:15 GMT 2023
|
PRIMARY | |||
|
m11752
Created by
admin on Sat Dec 16 01:29:15 GMT 2023 , Edited by admin on Sat Dec 16 01:29:15 GMT 2023
|
PRIMARY | |||
|
SUB126168
Created by
admin on Sat Dec 16 01:29:15 GMT 2023 , Edited by admin on Sat Dec 16 01:29:15 GMT 2023
|
PRIMARY | |||
|
870281-82-6
Created by
admin on Sat Dec 16 01:29:15 GMT 2023 , Edited by admin on Sat Dec 16 01:29:15 GMT 2023
|
PRIMARY | |||
|
82701
Created by
admin on Sat Dec 16 01:29:15 GMT 2023 , Edited by admin on Sat Dec 16 01:29:15 GMT 2023
|
PRIMARY | |||
|
DTXSID701007266
Created by
admin on Sat Dec 16 01:29:15 GMT 2023 , Edited by admin on Sat Dec 16 01:29:15 GMT 2023
|
PRIMARY | |||
|
N0000190114
Created by
admin on Sat Dec 16 01:29:15 GMT 2023 , Edited by admin on Sat Dec 16 01:29:15 GMT 2023
|
PRIMARY | Cytochrome P450 3A Inhibitors [MoA] | ||
|
C78825
Created by
admin on Sat Dec 16 01:29:15 GMT 2023 , Edited by admin on Sat Dec 16 01:29:15 GMT 2023
|
PRIMARY | |||
|
Idelalisib
Created by
admin on Sat Dec 16 01:29:15 GMT 2023 , Edited by admin on Sat Dec 16 01:29:15 GMT 2023
|
PRIMARY | |||
|
6741
Created by
admin on Sat Dec 16 01:29:15 GMT 2023 , Edited by admin on Sat Dec 16 01:29:15 GMT 2023
|
PRIMARY | |||
|
YG57I8T5M0
Created by
admin on Sat Dec 16 01:29:15 GMT 2023 , Edited by admin on Sat Dec 16 01:29:15 GMT 2023
|
PRIMARY | |||
|
YG57I8T5M0
Created by
admin on Sat Dec 16 01:29:15 GMT 2023 , Edited by admin on Sat Dec 16 01:29:15 GMT 2023
|
PRIMARY | |||
|
4878
Created by
admin on Sat Dec 16 01:29:15 GMT 2023 , Edited by admin on Sat Dec 16 01:29:15 GMT 2023
|
PRIMARY | |||
|
9624
Created by
admin on Sat Dec 16 01:29:15 GMT 2023 , Edited by admin on Sat Dec 16 01:29:15 GMT 2023
|
PRIMARY | |||
|
CHEMBL2216870
Created by
admin on Sat Dec 16 01:29:15 GMT 2023 , Edited by admin on Sat Dec 16 01:29:15 GMT 2023
|
PRIMARY | |||
|
AB-74
Created by
admin on Sat Dec 16 01:29:15 GMT 2023 , Edited by admin on Sat Dec 16 01:29:15 GMT 2023
|
PRIMARY | |||
|
11625818
Created by
admin on Sat Dec 16 01:29:15 GMT 2023 , Edited by admin on Sat Dec 16 01:29:15 GMT 2023
|
PRIMARY | |||
|
C78825
Created by
admin on Sat Dec 16 01:29:15 GMT 2023 , Edited by admin on Sat Dec 16 01:29:15 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
TRANSPORTER -> INHIBITOR |
|
||
|
TRANSPORTER -> SUBSTRATE | |||
|
BINDER->LIGAND |
BINDING
|
||
|
TARGET->WEAK INHIBITOR | |||
|
TRANSPORTER -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> INHIBITOR |
IN VITRO
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
METABOLIC ENZYME -> INHIBITOR |
IN VITRO
|
||
|
METABOLIC ENZYME -> INHIBITOR |
INN VITRO
|
||
|
TRANSPORTER -> INHIBITOR |
|
||
|
METABOLIC ENZYME -> INHIBITOR |
IN VITRO
|
||
|
TARGET -> INHIBITOR |
IC50
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE INACTIVE -> PARENT |
MAJOR
PLASMA
|
||
|
METABOLITE INACTIVE -> PARENT |
MAJOR
PLASMA
|
||
|
METABOLITE -> PARENT | |||
|
METABOLITE INACTIVE -> PARENT |
MAJOR
PLASMA
|
||
|
METABOLITE INACTIVE -> PARENT |
MAJOR
PLASMA
|
||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT | |||
|
METABOLITE INACTIVE -> PARENT |
MAJOR
PLASMA
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
blood-to-plasma ratio | PHARMACOKINETIC |
|
|
|||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Tmax | PHARMACOKINETIC |
|
|
|||